多发性硬化症患者的淀粉样蛋白-β病理变化率意外降低

IF 8.1 1区医学 Q1 CLINICAL NEUROLOGY

Annals of Neurology Pub Date : 2024-07-04 DOI:10.1002/ana.27027

Matthew R. Brier MD, PhD, Suzanne E. Schindler, Amber Salter, Dana Perantie, Nicole Shelley, Bradley Judge, Sarah Keefe, Kristopher M. Kirmess, Philip B. Verghese PhD, Kevin E. Yarasheski, Venky Venkatesh, Cyrus A. Raji, Brian A. Gordon, Randall J. Bateman, John C. Morris, Robert T. Naismith, David M. Holtzman, Tammie L.S. Benzinger, Anne H. Cross

{"title":"多发性硬化症患者的淀粉样蛋白-β病理变化率意外降低","authors":"Matthew R. Brier MD, PhD, Suzanne E. Schindler, Amber Salter, Dana Perantie, Nicole Shelley, Bradley Judge, Sarah Keefe, Kristopher M. Kirmess, Philip B. Verghese PhD, Kevin E. Yarasheski, Venky Venkatesh, Cyrus A. Raji, Brian A. Gordon, Randall J. Bateman, John C. Morris, Robert T. Naismith, David M. Holtzman, Tammie L.S. Benzinger, Anne H. Cross","doi":"10.1002/ana.27027","DOIUrl":null,"url":null,"abstract":"<p>The life expectancy of people with multiple sclerosis (MS) has increased, yet we have noted that development of a typical Alzheimer disease dementia syndrome is uncommon. We hypothesized that Alzheimer disease pathology is uncommon in MS patients. In 100 MS patients, the rate of amyloid-β plasma biomarker positivity was approximately half the rate in 300 non-MS controls matched on age, sex, apolipoprotein E proteotype, and cognitive status. Interestingly, most MS patients who did have amyloid-β pathology had features atypical for MS at diagnosis. These results support that MS is associated with reduced Alzheimer disease risk, and suggest new avenues of research. ANN NEUROL 2024;96:453–459</p>","PeriodicalId":127,"journal":{"name":"Annals of Neurology","volume":null,"pages":null},"PeriodicalIF":8.1000,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis Patients\",\"authors\":\"Matthew R. Brier MD, PhD, Suzanne E. Schindler, Amber Salter, Dana Perantie, Nicole Shelley, Bradley Judge, Sarah Keefe, Kristopher M. Kirmess, Philip B. Verghese PhD, Kevin E. Yarasheski, Venky Venkatesh, Cyrus A. Raji, Brian A. Gordon, Randall J. Bateman, John C. Morris, Robert T. Naismith, David M. Holtzman, Tammie L.S. Benzinger, Anne H. Cross\",\"doi\":\"10.1002/ana.27027\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The life expectancy of people with multiple sclerosis (MS) has increased, yet we have noted that development of a typical Alzheimer disease dementia syndrome is uncommon. We hypothesized that Alzheimer disease pathology is uncommon in MS patients. In 100 MS patients, the rate of amyloid-β plasma biomarker positivity was approximately half the rate in 300 non-MS controls matched on age, sex, apolipoprotein E proteotype, and cognitive status. Interestingly, most MS patients who did have amyloid-β pathology had features atypical for MS at diagnosis. These results support that MS is associated with reduced Alzheimer disease risk, and suggest new avenues of research. ANN NEUROL 2024;96:453–459</p>\",\"PeriodicalId\":127,\"journal\":{\"name\":\"Annals of Neurology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":8.1000,\"publicationDate\":\"2024-07-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Neurology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/ana.27027\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Neurology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ana.27027","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

多发性硬化症（MS）患者的预期寿命延长了，但我们注意到，典型的阿尔茨海默病痴呆综合征并不常见。我们假设阿尔茨海默病的病理变化在多发性硬化症患者中并不常见。在 100 名多发性硬化症患者中，淀粉样蛋白-β血浆生物标志物阳性率约为 300 名年龄、性别、载脂蛋白 E 蛋白型和认知状况相匹配的非多发性硬化症对照组的一半。有趣的是，大多数出现淀粉样蛋白-β病理变化的多发性硬化症患者在确诊时具有多发性硬化症的非典型特征。这些结果支持多发性硬化症与阿尔茨海默病风险降低有关，并提出了新的研究途径。ann neurol 2024.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis Patients

The life expectancy of people with multiple sclerosis (MS) has increased, yet we have noted that development of a typical Alzheimer disease dementia syndrome is uncommon. We hypothesized that Alzheimer disease pathology is uncommon in MS patients. In 100 MS patients, the rate of amyloid-β plasma biomarker positivity was approximately half the rate in 300 non-MS controls matched on age, sex, apolipoprotein E proteotype, and cognitive status. Interestingly, most MS patients who did have amyloid-β pathology had features atypical for MS at diagnosis. These results support that MS is associated with reduced Alzheimer disease risk, and suggest new avenues of research. ANN NEUROL 2024;96:453–459

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Annals of Neurology 医学-临床神经学

CiteScore

18.00

自引率

1.80%

发文量

270

审稿时长

3-8 weeks

期刊介绍： Annals of Neurology publishes original articles with potential for high impact in understanding the pathogenesis, clinical and laboratory features, diagnosis, treatment, outcomes and science underlying diseases of the human nervous system. Articles should ideally be of broad interest to the academic neurological community rather than solely to subspecialists in a particular field. Studies involving experimental model system, including those in cell and organ cultures and animals, of direct translational relevance to the understanding of neurological disease are also encouraged.